Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594230 · ClinicalTrials.gov registry record · Phase 2
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase 2 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00594230 is a Phase 2 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 26 participants.
The verdict
NCT00594230, a Phase 2 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This will be a single arm Phase II study.
Interventions
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594230
The ClinicalTrials.gov registry entry for NCT00594230 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panobinostat is the first listed.
NCT00594230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00594230 about?
NCT00594230 is a clinical study titled "LBH589 in Refractory Myelodysplastic Syndromes (MDS)". This will be a single arm Phase II study.
What is the current status of trial NCT00594230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-01. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00594230?
The interventions under investigation include: Panobinostat (DRUG).
Who is sponsoring clinical trial NCT00594230?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.